1. Home
  2. /
  3. Venture Capital
  4. /
  5. MRM Health and IFF...

Venture Capital

MRM Health and IFF Reach Second Milestone in the partnered Type 2 Diabetes program

14 December 2022
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets.

Download

Press Release
Download

Related News

arrow-up-right
Deepull-logo
arrow-up-right